Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03805581 · ClinicalTrials.gov registry record · Phase 2
Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome
A Phase 2 study, sponsored by New York Medical College.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT03805581 is a Phase 2 study that has completed, run by New York Medical College. The registered enrollment target is 20 participants.
The verdict
NCT03805581, a Phase 2 study, has completed, sponsored by New York Medical College.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study evaluates the safety of defibrotide in subjects with sickle cell disease (SCD)-associated acute chest syndrome (ACS).
Interventions
- DRUG Defibrotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-01-12 |
| Est. Completion | 2023-11-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03805581
The ClinicalTrials.gov registry entry for NCT03805581 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York Medical College, which has 47 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Defibrotide is the first listed.
NCT03805581 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03805581 about?
NCT03805581 is a clinical study titled "Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome". This study evaluates the safety of defibrotide in subjects with sickle cell disease (SCD)-associated acute chest syndrome (ACS).
What is the current status of trial NCT03805581?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2018-01-12. Estimated completion is 2023-11-07.
What interventions are being tested in trial NCT03805581?
The interventions under investigation include: Defibrotide (DRUG).
Who is sponsoring clinical trial NCT03805581?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.